BRPI0507482A - combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap - Google Patents
combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iapInfo
- Publication number
- BRPI0507482A BRPI0507482A BRPI0507482-7A BRPI0507482A BRPI0507482A BR PI0507482 A BRPI0507482 A BR PI0507482A BR PI0507482 A BRPI0507482 A BR PI0507482A BR PI0507482 A BRPI0507482 A BR PI0507482A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- inhibitor
- iap
- dna topoisomerase
- treating
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 title 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 101710183280 Topoisomerase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 abstract 1
- 102000004039 Caspase-9 Human genes 0.000 abstract 1
- 108090000566 Caspase-9 Proteins 0.000 abstract 1
- 229940121863 DNA inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000158 apoptosis inhibitor Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMBINAçãO DE (A) UM INIBIDOR DE DNA TOPOISOMERASE E (B) UM INIBIDOR DE IAP. A presente invenção refere-se a uma combinação farmacêutica que compreende (a) um composto inibidor de DNA topoisomerase e (b) um composto que inibe as propriedades de inibição da caspase-9 de um inibidor de apoptose de proteína (IAP) para o tratamento de uma doença proliferativa, especialmente uma doença de tumor sólido; a uma composição farmacêutica que compreende uma tal combinação; ao uso de uma tal combinação para a preparação de um medicamento para o tratamento de uma doença proliferativa; a uma embalagem comercial ou produto que compreenda uma tal combinação com uma preparação combinada para uso simultâneo, separado ou seqüencial e a um método de tratamento de um animal de sangue, especialmente de um ser humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54198404P | 2004-02-05 | 2004-02-05 | |
| PCT/EP2005/001180 WO2005074989A2 (en) | 2004-02-05 | 2005-02-04 | Combination of a dna topoisomerase inhibitor and an iap inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507482A true BRPI0507482A (pt) | 2007-07-17 |
Family
ID=34837537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507482-7A BRPI0507482A (pt) | 2004-02-05 | 2005-02-04 | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110251134A1 (pt) |
| EP (1) | EP1713542A2 (pt) |
| JP (1) | JP2007520522A (pt) |
| KR (1) | KR20060126548A (pt) |
| CN (1) | CN1953744A (pt) |
| AU (1) | AU2005210137B2 (pt) |
| BR (1) | BRPI0507482A (pt) |
| CA (1) | CA2552937A1 (pt) |
| RU (1) | RU2006131553A (pt) |
| WO (1) | WO2005074989A2 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2475207T3 (es) | 2004-07-15 | 2014-07-10 | Tetralogic Pharmaceuticals Corporation | Compuestos de unión a IAP |
| DK1851200T3 (da) | 2005-02-25 | 2014-04-14 | Tetralogic Pharm Corp | Dimere iap-inhibitorer |
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| US8143426B2 (en) | 2006-07-24 | 2012-03-27 | Tetralogic Pharmaceuticals Corporation | IAP inhibitors |
| CA2657706A1 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001061484A (ja) * | 1999-06-23 | 2001-03-13 | Sankyo Co Ltd | アポトーシス抑制活性を有するポリヌクレオチド |
| EP1465649A4 (en) * | 2001-11-21 | 2007-07-11 | Burnham Inst | METHODS AND COMPOSITIONS FOR IAP-INHIBITED CASPASE DERPRESSION (APOPTOSIS PROTEIN INHIBITOR) |
| CA2480308C (en) * | 2002-03-27 | 2011-10-04 | Aegera Therapeutics Inc. | Antisense iap nucleobase oligomers and uses thereof |
| EP1354953A1 (en) * | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| JP4541882B2 (ja) * | 2002-07-02 | 2010-09-08 | ノバルティス アーゲー | Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤 |
-
2005
- 2005-02-04 EP EP05707223A patent/EP1713542A2/en not_active Withdrawn
- 2005-02-04 CN CNA2005800030364A patent/CN1953744A/zh active Pending
- 2005-02-04 RU RU2006131553/15A patent/RU2006131553A/ru not_active Application Discontinuation
- 2005-02-04 JP JP2006551818A patent/JP2007520522A/ja active Pending
- 2005-02-04 CA CA002552937A patent/CA2552937A1/en not_active Abandoned
- 2005-02-04 BR BRPI0507482-7A patent/BRPI0507482A/pt not_active IP Right Cessation
- 2005-02-04 AU AU2005210137A patent/AU2005210137B2/en not_active Ceased
- 2005-02-04 WO PCT/EP2005/001180 patent/WO2005074989A2/en active Application Filing
- 2005-02-04 US US10/587,758 patent/US20110251134A1/en not_active Abandoned
- 2005-02-04 KR KR1020067015819A patent/KR20060126548A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005210137B2 (en) | 2009-06-04 |
| US20110251134A1 (en) | 2011-10-13 |
| JP2007520522A (ja) | 2007-07-26 |
| RU2006131553A (ru) | 2008-03-10 |
| WO2005074989A3 (en) | 2006-11-09 |
| CN1953744A (zh) | 2007-04-25 |
| CA2552937A1 (en) | 2005-08-18 |
| KR20060126548A (ko) | 2006-12-07 |
| EP1713542A2 (en) | 2006-10-25 |
| WO2005074989A2 (en) | 2005-08-18 |
| AU2005210137A1 (en) | 2005-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
| BR0316004A (pt) | Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina | |
| MX336723B (es) | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. | |
| BR112014011645A2 (pt) | combinação de um inibidor da fosfoinositida 3-quinase e um modulador da quinase janus 2-transdutor de sinal e ativador da via de transcrição 5 | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| MX2009002054A (es) | Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. | |
| JO3265B1 (ar) | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض | |
| EA200602047A1 (ru) | Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| WO2006133707A3 (en) | Anti-cancer combination treatment and kit-of-part | |
| TN2009000213A1 (en) | Combination | |
| BR0307629A (pt) | Métodos e composições para tratar condições hiperproliferativas | |
| HK1075208A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| IL284930A (en) | History of pyrrolopyrimidines and their use in the treatment of protein kinase-related diseases | |
| BRPI1008103A2 (pt) | " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos " | |
| MX2011012201A (es) | Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico. | |
| BRPI0715609A2 (pt) | Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| BRPI0418801A (pt) | métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit | |
| BR0316021A (pt) | Comibinação compreendendo um inibidor de cdk e cisplatina | |
| BR0316029A (pt) | Combinação | |
| BR0316010A (pt) | Combinação | |
| WO2007054725A3 (en) | Combination of a cdk-inhibitor and a hdac-inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |